Joseph W. Collard
Chief Executive Officer
Mr. Collard founded Epigenetix in 2011 and has since served as CEO. He is also the founder of numerous companies, notably Technisource, which emerged as an international NASDAQ firm. Here, Mr. Collard served as Chairman and CEO from its inception right through reaching annual sales of 250 million dollars in 2002.
Claes Wahlestedt, Ph.D., M.D.
Chief Science Officer
Dr. Wahlestedt is the Leonard M. Miller Professor at the University of Miami and is spearheading a range of drug discovery and translational efforts in his roles as Associate Dean and Center Director for Therapeutic Innovation. He is the author of more than 200 research papers and has ongoing research projects concerning epigenetics, mammalian transcriptomics, noncoding RNAs, neuroscience, cancer and drug discovery across several therapeutic areas. A native of Sweden, Claes obtained his M.D. and Ph.D. degrees from Lund University, and then went on to develop an international career in academia as well as in the pharmaceutical industry. Before joining the University of Miami, Dr. Wahlestedt was a professor and director of neuroscience discovery at the new Florida campus of The Scripps Research Institute (2005-2011). Before that he was an endowed professor and chair of the Department for Genomics and Bioinformatics at the Karolinska Institute in Stockholm (1997-2005). Previously, he also directed large drug discovery and biotechnology teams in the pharmaceutical industry for Astra-Zeneca, Pharmacia & Upjohn, and Pharmacia Corporation. His most recent biotechnology start-up was CURNA Inc. which was acquired by OPKO Health in 2011.
Jeffrey Albert, Ph.D.
Director of Chemistry
Dr. Albert has a 20-year track record in the identification and validation of new drug targets, discovering initial chemical leads, and in advancing those leads through pre-clinical discovery to Phase-1. He served as Head of Lead Generation in Neuroscience Chemistry at AstraZeneca. He has authored or co-authored 4 book chapters, 32 scientific publications, filed more than 40 patents, and frequently lectures on drug discovery both in the United States and internationally.
Christoffer Landqvist, M.Sc., MBA
Chief Financial Officer
Mr. Landqvist, the second Swedish native on staff, is overseeing the company’s financial and strategic branding initiatives. Prior to joining Epigenetix, he served as both country director and Jr. CFO for C&C Hedge International. Mr. Landqvist brings more than 10 years of global financial management experience to the company. Before his permanent move to the United States in 2006, he held a broad range of senior management roles in Europe. Mr. Landqvist holds a M.Sc. from Pittsburg State University and an MBA from Washburn University.
Shaun Brothers, Ph.D.
Director of Pharmacology
Dr. Brothers has 16 years of experience in pharmacology, drug discovery and related fields. He is the Assistant Professor and founding member of the Center for Therapeutic Innovation at the University of Miami Miller School of Medicine. Dr. Brothers spent 5 years doing drug discovery and development at the new Scripps Florida campus in Jupiter, FL. He completed his graduate training in Physiology and Pharmacology at the Oregon National Primate Research Center and Oregon Health & Science University. In addition, he holds a Bachelors degree in Microbiology and Chemistry from Oregon State University.
Nagi Ayad, Ph.D.
Director of Oncology
Dr. Ayad is a cell biologist by training and has worked on enzymatic regulation of mitotic cell divisions in neuronal precursors. Dr. Ayad received his Ph.D. degree from Yale Medical School in 1998 and completed his postdoctoral training from Harvard Medical School in 2004. He served as an assistant professor at the Scripps Research Institute in Jupiter, Florida prior to joining University of Miami.